MaaT Pharma has seen its microbiome therapy for patients living with treatment-induced dysbiosis hit its endpoints.

Suven Life Sciences has announced the dosing of the first subjects in its Phase I clinical trial of SUVN-I6107 to treat cognitive disorders.

Viking Therapeutics has begun a Phase II clinical trial of VK2735 aimed at treating metabolic disorders, such as obesity.

Cervical cancer begins in the cells of the cervix and is primarily caused by the human papillomavirus (HPV), a common sexually transmitted virus.

ISM5411 was well tolerated and demonstrated a favourable pharmokinetic profile in validating gut-restrictive properties.

The company says the early trial of its hair-loss therapy saw patients benefit from six times more hair growth than placebo.

Ryght AI has announced a strategic collaboration with QPS Holdings for optimising clinical trial processes globally.

RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

J&J has reported positive topline outcomes from the MARIPOSA trial of RYBREVANT and LAZCLUZE combo for NSCLC treatment.

BIAL has completed the full dose regimen for the first subject in the Phase II ACTIVATE trial of BIA 28-6156, for Parkinson's treatment.

Denali Therapeutics has reported that its Phase II/III HEALEY ALS Platform trial of DNL343 for ALS failed to meet its primary endpoint.

VYNE Therapeutics has completed enrolment in the randomised Phase IIb clinical trial of VYN201 gel for treating non-segmental vitiligo.